Larimar Therapeutics Inc Stock Price, News & Analysis

Larimar Therapeutics (Nasdaq: LRMR) announced that its biomarker studies on Friedreich's ataxia will be presented at the Gordon Research Conference on Mitochondria and Chloroplasts from July 17-22, 2022. The study highlights differentially expressed genes between healthy individuals and those with Friedreich's ataxia, focusing on potential treatment pathways. The oral presentation will occur on July 21, 2022, at 8:40 PM ET by David Bettoun, Ph.D., the company's Vice President of Discovery and Non-clinical R&D.

BALA CYNWYD, Pa., June 2, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced its participation in two upcoming conferences. At the United Mitochondrial Disease Foundation Mitochondrial Medicine 2022 on June 9, 2022, Dr. Matthew Baile will discuss CTI-1601's effects on neurodegeneration. The company will also present on June 15, 2022, at the XXIV World Congress International Society for Heart Research, focusing on lipidomic insights related to Friedreich's ataxia and heart failure.

Larimar Therapeutics (Nasdaq: LRMR) announced that data from its Phase 1 clinical trial of CTI-1601 for treating Friedreich's ataxia will be presented at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, on May 26, 2022. The posters will cover the increase of tissue frataxin levels post-administration and the safety and pharmacokinetics of the therapy. This highlights Larimar's focus on developing treatments for complex rare diseases and advancing its clinical programs.

Larimar Therapeutics (LRMR) announced a Type C FDA meeting scheduled for early Q3 2022 to address the ongoing clinical hold on its CTI-1601 program. This meeting aims to resolve issues related to previous mortalities in a non-human primate study, which led to the hold. As of March 31, 2022, Larimar reported $62.6 million in cash, indicating a runway into Q3 2023. The company recorded a net loss of $8.9 million for Q1 2022, an improvement from $12.1 million in Q1 2021, while R&D expenses decreased from $9.0 million to $5.8 million.

Larimar Therapeutics (Nasdaq: LRMR) reported its full-year 2021 financial results, highlighting clinical progress in developing CTI-1601 for Friedreich’s ataxia. Positive Phase 1 trial data indicated dose-dependent increases in frataxin levels, showing that CTI-1601 is generally well tolerated. Despite these advancements, the FDA's clinical hold remains in effect, necessitating more data. For 2021, the company recorded a net loss of $50.6 million, or $2.95 per share, with R&D expenses rising to $38.4 million. Cash reserves stood at $70.1 million as of year-end 2021.

Larimar Therapeutics (Nasdaq: LRMR) announced that the FDA is maintaining its clinical hold on the CTI-1601 program, requiring additional data for resolution. The company is reassessing its study plans and aims to engage the FDA for guidance. Despite this setback, Larimar believes there is a path forward based on existing data from Phase 1 trials, which showed CTI-1601 was generally well tolerated. The company emphasizes its commitment to CTI-1601 and has a strong cash position to support operations through at least 2023 while managing burn rates under a cost reduction plan.

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced management participation in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The company is focused on developing treatments for complex rare diseases, particularly its lead compound CTI-1601, which is undergoing a Phase 1 clinical program for Friedreich's ataxia. Larimar aims to leverage its intracellular delivery platform to create new fusion proteins for additional rare diseases.

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced its participation in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference on November 15-16, 2021. The company focuses on developing treatments for complex rare diseases, with its lead compound CTI-1601 currently in a Phase 1 clinical program targeting Friedreich's ataxia. Larimar aims to utilize its intracellular delivery platform for other fusion proteins aimed at rare diseases characterized by deficiencies in intracellular bioactive compounds.

Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported its third quarter and year-to-date results as of September 30, 2021. The company has a strong balance sheet with $78 million in cash and marketable securities. Despite a clinical hold on its CTI-1601 program by the FDA due to safety concerns, they have compelling Phase 1 data and are focused on addressing Friedreich’s ataxia. The net loss for Q3 2021 was $16.8 million ($0.92 per share), increasing from $10.3 million in Q3 2020. R&D expenses rose to $14 million from $6.9 million in Q3 2020, driven by higher clinical supply costs.